Literature DB >> 26110221

Methadone Medical Maintenance: An Early 21st-Century Perspective.

David M Novick1, Edwin A Salsitz, Herman Joseph, Mary Jeanne Kreek.   

Abstract

Methadone medical maintenance is the treatment of stable methadone-maintained patients in primary care physicians' offices under an exemption from federal methadone regulations. Reports from seven such programs in six states show high retention and low frequencies of illicit drug use. Patients and physicians indicate high levels of satisfaction. Although methadone maintenance has a long history of safety and efficacy, most methadone medical maintenance programs are no longer operating or accepting new patients. Federal regulations for standard methadone clinics allow some features of methadone medical maintenance, and advocacy for state approval of these changes is strongly recommended.

Entities:  

Keywords:  Review; addiction; buprenorphine; heroin; methadone; opioid; pharmacotherapy; primary care

Mesh:

Substances:

Year:  2015        PMID: 26110221     DOI: 10.1080/10550887.2015.1059225

Source DB:  PubMed          Journal:  J Addict Dis        ISSN: 1055-0887


  16 in total

1.  Opioid-galanin receptor heteromers differentiate the dopaminergic effects of morphine and methadone.

Authors:  Randal A Serafini; Venetia Zachariou
Journal:  J Clin Invest       Date:  2019-05-28       Impact factor: 14.808

2.  The highly selective dopamine D3R antagonist, R-VK4-40 attenuates oxycodone reward and augments analgesia in rodents.

Authors:  Chloe J Jordan; Bree Humburg; Myra Rice; Guo-Hua Bi; Zhi-Bing You; Anver Basha Shaik; Jianjing Cao; Alessandro Bonifazi; Alexandra Gadiano; Rana Rais; Barbara Slusher; Amy Hauck Newman; Zheng-Xiong Xi
Journal:  Neuropharmacology       Date:  2019-04-08       Impact factor: 5.250

3.  Counseling Staff's Views of Patient-Centered Methadone Treatment: Changing Program Rules and Staff Roles.

Authors:  Shannon Gwin Mitchell; Laura B Monico; Elizabeth Lertch; Sharon M Kelly; Jan Gryczynski; Jerome H Jaffe; Kevin E O'Grady; Robert P Schwartz
Journal:  J Behav Health Serv Res       Date:  2018-07       Impact factor: 1.505

4.  Sex Differences in Regional Brain Glucose Metabolism Following Opioid Withdrawal and Replacement.

Authors:  Giovanni C Santoro; Joseph Carrion; Krishna Patel; Crystal Vilchez; Jennifer Veith; Jonathan D Brodie; Stephen L Dewey
Journal:  Neuropsychopharmacology       Date:  2017-04-10       Impact factor: 7.853

5.  Office-based Methadone Prescribing for Opioid Use Disorder: The Canadian Model.

Authors:  Robert A Kleinman; Thomas D Brothers; Marlon Danilewitz; Anees Bahji
Journal:  J Addict Med       Date:  2022-01-11       Impact factor: 4.647

6.  The novel dopamine D3 receptor antagonists/partial agonists CAB2-015 and BAK4-54 inhibit oxycodone-taking and oxycodone-seeking behavior in rats.

Authors:  Zhi-Bing You; Jun-Tao Gao; Guo-Hua Bi; Yi He; Comfort Boateng; Jianjing Cao; Eliot L Gardner; Amy Hauck Newman; Zheng-Xiong Xi
Journal:  Neuropharmacology       Date:  2017-09-06       Impact factor: 5.250

Review 7.  Pharmacotherapy of Opioid Addiction: "Putting a Real Face on a False Demon".

Authors:  E Salsitz; T Wiegand
Journal:  J Med Toxicol       Date:  2016-03

Review 8.  Medications for substance use disorders (SUD): emerging approaches.

Authors:  Eduardo R Butelman; Mary Jeanne Kreek
Journal:  Expert Opin Emerg Drugs       Date:  2017-10-30       Impact factor: 4.191

9.  Selective dopamine D3 receptor antagonist YQA14 inhibits morphine-induced behavioral sensitization in wild type, but not in dopamine D3 receptor knockout mice.

Authors:  Yang Lv; Rong-Rong Hu; Manyi Jing; Tai-Yun Zhao; Ning Wu; Rui Song; Jin Li; Gang Hu
Journal:  Acta Pharmacol Sin       Date:  2018-09-17       Impact factor: 6.150

10.  Research priorities for expanding access to methadone treatment for opioid use disorder in the United States: A National Institute on Drug Abuse Center for Clinical Trials Network Task Force report.

Authors:  Paul J Joudrey; Gavin Bart; Robert K Brooner; Lawrence Brown; Julie Dickson-Gomez; Adam Gordon; Sarah S Kawasaki; Jane M Liebschutz; Edward Nunes; Dennis McCarty; Robert P Schwartz; José Szapocnik; Madhukar Trivedi; Judith I Tsui; Arthur Williams; Li-Tzy Wu; David A Fiellin
Journal:  Subst Abus       Date:  2021       Impact factor: 3.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.